Liu Xiqiang, Yu Jinsheng, Jiang Lu, Wang Anxun, Shi Fei, Ye Hui, Zhou Xiaofeng
Center for Molecular Biology of Oral Diseases, College of Dentistry, University of Illinois at Chicago, Chicago, IL 60612-7213, USA.
Cancer Genomics Proteomics. 2009 May-Jun;6(3):131-9.
MicroRNA deregulation is involved in tumor initiation and progression. The aim of this study was to identify and validate the microRNA candidates that contribute to the metastasis of oral tongue squamous cell carcinoma (OTSCC). Using microarrays, a panel of differentially expressed microRNAs was identified in paired OTSCC cell lines with different metastatic potential. Selected microRNA candidates (including hsa-miR-222) were further validated using quantitative PCR approach. Functional analysis indicated that hsa-miR-222 inhibits OTSCC cell invasion. Ectopic transfection of hsa-miR-222 reduced the expression of MMP1 and SOD2 in OTSCC cell lines. Direct targeting of hsa-miR-222 to specific sequences located in the 3'-untranslated regions of both MMP1 and SOD2 mRNAs were confirmed using luciferase reporter gene assays. Furthermore, SOD2 knockdown by siRNA led to the downregulation of MMP1 expression. Taken together, these results suggested that hsa-miR-222 regulates the MMP1 expression through both direct cis-regulatory mechanism (targeting MMP1 mRNA) and indirect trans-regulatory mechanism (indirect controlling of MMP1 gene expression by targeting SOD2). Our results indicate that hsa-miR-222 plays an important role in OTSCC invasion, and may serve as a novel therapeutic target for OTSCC patients at risk of metastatic disease.
微小RNA失调与肿瘤的发生和发展有关。本研究的目的是鉴定并验证促成口腔舌鳞状细胞癌(OTSCC)转移的微小RNA候选物。利用微阵列技术,在具有不同转移潜能的配对OTSCC细胞系中鉴定出一组差异表达的微小RNA。使用定量PCR方法进一步验证了所选的微小RNA候选物(包括hsa-miR-222)。功能分析表明,hsa-miR-222抑制OTSCC细胞侵袭。hsa-miR-222的异位转染降低了OTSCC细胞系中MMP1和SOD2的表达。使用荧光素酶报告基因测定法证实了hsa-miR-222直接靶向位于MMP1和SOD2 mRNA的3'-非翻译区的特定序列。此外,通过siRNA敲低SOD2导致MMP1表达下调。综上所述,这些结果表明,hsa-miR-222通过直接顺式调节机制(靶向MMP1 mRNA)和间接反式调节机制(通过靶向SOD2间接控制MMP1基因表达)调节MMP1表达。我们的结果表明,hsa-miR-222在OTSCC侵袭中起重要作用,并可能作为有转移疾病风险的OTSCC患者的新型治疗靶点。